Should I buy or sell Aytu BioPharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AYTU shares. View AYTU analyst ratings or view top-rated stocks .

What is Aytu BioPharma's stock price target for 2024?

1 Wall Street research analysts have issued 1-year target prices for Aytu BioPharma's shares. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 79.2% from the stock's current price. View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts .

How have AYTU shares performed in 2024?

Aytu BioPharma's stock was trading at $2.84 at the beginning of the year. Since then, AYTU stock has decreased by 1.8% and is now trading at $2.79. View the best growth stocks for 2024 here .

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AYTU earnings forecast .

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) posted its earnings results on Wednesday, February, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business earned $22.93 million during the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 41.00% and a negative net margin of 18.27%.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE) , Vaxart (VXRT) , ADMA Biologics (ADMA) , Heat Biologics (HTBX) , Inovio Pharmaceuticals (INO) , VBI Vaccines (VBIV) , iBio (IBIO) , Matinas BioPharma (MTNB) , Bionano Genomics (BNGO) and SCYNEXIS (SCYX) .

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AYTU Stock Alerts

$2.79

-0.08 (-2.79%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.79
▼
$2.93
50-Day Range: $2.65
▼
$3.36
52-Week Range: $1.38
▼
$3.50

Volume: 3,294 shs
Average Volume: 19,695 shs
Market Capitalization: $15.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Aytu BioPharma alerts:

Aytu BioPharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 79.2% Upside
$5.00 Price Target
Short Interest: Bearish
6.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.45
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

485th out of 918 stocks

Pharmaceutical Preparations Industry

210th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Aytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aytu BioPharma has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.73% of the float of Aytu BioPharma has been sold short.
Short Interest Ratio / Days to Cover
Aytu BioPharma has a short interest ratio ("days to cover") of 18, which indicates bearish sentiment.
Change versus previous month
Short interest in Aytu BioPharma has recently decreased by 0.19%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aytu BioPharma does not currently pay a dividend.
Dividend Growth
Aytu BioPharma does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Aytu BioPharma has received a 39.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Carbinoxamine", "Methylphenidate", and "Amphetamine" products. See details.
Environmental Sustainability
The Environmental Impact score for Aytu BioPharma is -2.45.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.34% of the stock of Aytu BioPharma is held by insiders.
Percentage Held by Institutions
Only 33.49% of the stock of Aytu BioPharma is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Aytu BioPharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aytu BioPharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aytu BioPharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Aytu BioPharma Stock (NASDAQ:AYTU)

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

AYTU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AYTU Stock News Headlines

April 17, 2024 | morningstar.com

Aytu BioPharma Inc 0A8M

April 2, 2024 | msn.com

RedHill Biopharma looks to raise $1.25M in a direct offering of securities

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 24, 2024 | morningstar.com

Aytu BioPharma Inc AYTU

March 19, 2024 | seekingalpha.com

Seelos drops as lead drug fails in ALS trial

March 18, 2024 | seekingalpha.com

Seelos Therapeutics files for 3.4M shares secondary offering

February 25, 2024 | msn.com

Aytu BioPharma (AYTU) Price Target Increased by 60.00% to 8.16

February 16, 2024 | finance.yahoo.com

Aytu BioPharma Second Quarter 2024 Earnings: Beats Expectations

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 16, 2024 | finance.yahoo.com

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript

February 15, 2024 | finance.yahoo.com

Q2 2024 Aytu Biopharma Inc Earnings Call

February 14, 2024 | finance.yahoo.com

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

February 13, 2024 | benzinga.com

Earnings Preview: Aytu BioPharma

February 7, 2024 | finance.yahoo.com

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

January 23, 2024 | finance.yahoo.com

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

January 16, 2024 | finance.yahoo.com

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?

December 18, 2023 | benzinga.com

Aytu BioPharma Stock (NASDAQ:AYTU) Dividends: History, Yield and Dates

November 30, 2023 | finance.yahoo.com

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

November 15, 2023 | finance.yahoo.com

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript

November 14, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

November 14, 2023 | finance.yahoo.com

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

November 13, 2023 | markets.businessinsider.com

Aytu BioPharma earnings: here's what to expect

November 8, 2023 | finance.yahoo.com

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

November 7, 2023 | finance.yahoo.com

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

October 28, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

October 28, 2023 | markets.businessinsider.com

Aytu BioPharma: Strategic Manufacturing Transition and Financial Growth Bolster Buy Rating

October 26, 2023 | finance.yahoo.com

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

See More Headlines

Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AYTU
CUSIP: N/A
CIK: 1385818
Web: aytubio.com
Phone: (720) 437-6580
Fax: N/A
Employees: 150
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +79.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,050,000.00
Net Margins: -18.27%
Pretax Margin: -17.43%
Return on Equity: -41.00%
Return on Assets: -10.87%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 1.11
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $107.40 million
Price / Sales: 0.14
Cash Flow: $0.96 per share
Price / Cash Flow: 2.90
Book Value: $10.41 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 5,570,000
Free Float: 5,326,000
Market Cap: $15.54 million
Optionable: Not Optionable
Beta: -1.21

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Joshua R. Disbrow (Age 49)
Chairman & CEO
Comp: $708k
Mr. Mark K. Oki CPA (Age 55)
CFO, Secretary & Treasurer
Comp: $522.84k
Mr. Greg Pyszczymuka (Age 45)
Chief Commercial Officer
Comp: $525k
Ms. Victoria Cordova
Vice President of People & Culture
Mr. Jarrett T. Disbrow Ph.D. (Age 49)
Chief Business Officer & President of Consumer Health
Comp: $355k
Mr. Russ McMahen
Senior Vice President of Research & Development
Mr. Ryan J. Selhorn CPA (Age 42)
Executive VP of Finance & Business Optimization

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AYTU Stock Analysis - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings or view top-rated stocks.
What is Aytu BioPharma's stock price target for 2024?: 1 Wall Street research analysts have issued 1-year target prices for Aytu BioPharma's shares. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 79.2% from the stock's current price.
View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts.
How have AYTU shares performed in 2024?: Aytu BioPharma's stock was trading at $2.84 at the beginning of the year. Since then, AYTU stock has decreased by 1.8% and is now trading at $2.79.
View the best growth stocks for 2024 here.
When is Aytu BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AYTU earnings forecast.

How were Aytu BioPharma's earnings last quarter?: Aytu BioPharma, Inc. (NASDAQ:AYTU) posted its earnings results on Wednesday, February, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business earned $22.93 million during the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 41.00% and a negative net margin of 18.27%.
When did Aytu BioPharma's stock split?: Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Aytu BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).
How do I buy shares of Aytu BioPharma?: Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AYTU) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial